Heterocyclic analogues of xanthone and xanthione. 1H-pyrano[2,3-c:6,5-c] dipyrazol-4(7H)-ones and thiones: Synthesis and NMR data

Article abstract of DOI:10.3390/molecules15096106

The synthesis of the title compounds is described. Reaction of 1-substituted 2-pyrazolin-5-ones with 5-chloro-1-phenyl-1H-pyrazole-4-carbonyl chloride or 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbonyl chloride, respectively, using calcium hydroxide in refluxing 1,4-dioxane gave the corresponding 4-heteroaroylpyrazol-5-ols, which were cyclized into 1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-ones by treatment with K ₂CO₃/DMF. The latter were converted into the corresponding thiones upon reaction with Lawesson's reagent. Detailed NMR spectroscopic investigations (¹H, ¹³C, ¹⁵N) of the ring systems and their precursors are presented.

Full text of DOI:10.3390/molecules15096106

Molecules 2010, 15, 6106-6126; doi:10.3390/molecules15096106
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Heterocyclic Analogues of Xanthone and Xanthione.
1H-Pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-ones and Thiones:
Synthesis and NMR Data
Barbara Datterl *, Nicole Tröstner, Dorota Kucharski and Wolfgang Holzer *
Department of Drug and Natural Product Synthesis, Faculty of Life Sciences, University of Vienna,
Althanstrasse 14, A-1090 Vienna, Austria
* Authors to whom correspondence should be addressed; E-Mails: barbara.datterl@univie.ac.at
(B.D); wolfgang.holzer@univie.ac.at (W.H.)
Received: 28 July 2010; in revised form: 27 August 2010 / Accepted: 31 August 2010 /
Published: 1 September 2010
Abstract: The synthesis of the title compounds is described. Reaction of 1-substituted
2-pyrazolin-5-ones with 5-chloro-1-phenyl-1H-pyrazole-4-carbonyl chloride or 5-chloro-
3-methyl-1-phenyl-1H-pyrazole-4-carbonyl chloride, respectively, using calcium
hydroxide in refluxing 1,4-dioxane gave the corresponding 4-heteroaroylpyrazol-5-ols,
which were cyclized into 1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-ones by treatment with
K2CO3/DMF. The latter were converted into the corresponding thiones upon reaction with
13
15
Lawesson’s reagent. Detailed NMR spectroscopic investigations (1H, C, N) of the ring
systems and their precursors are presented.
Keywords: pyrazolones; 1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-ones; cyclization;
Lawesson’s reagent; NMR spectroscopy
1. Introduction
The xanthone system, shown in Figure 1, is the core of several biologically active compounds
which play important roles in numerous biological processes [1,2]. Thus, for instance, xanthone
derivatives with anti-cancer [3,4], cytotoxic [5,6], topoisomerase II inhibitory [5], monoamine oxidase
inhibitory [6], antioxidant [6], and antimicrobial activity [7] have been described in the recent

Molecules 2010, 15
6107
literature. In view of this fact synthetic derivatives of xanthones are attractive compounds for
medicinal chemists. As a result analogues in which one or both benzene rings of the parent xanthone
system had been replaced by heteroaromatic moieties were also studied. As a representative example
of these compounds the anti-ulcer agent amlexanox (Figure 1) may be cited [8].
In the course of a program devoted to the synthesis of new heterocyclic scaffolds for bioactive
compounds we recently presented the synthesis of various [5,6]pyrano[2,3-c]pyrazol-4(1H)-ones of
type 4, which can be considered as heterocyclic analogues of xanthone (Scheme 1) [9-16]. The
synthesis of compounds 4 is based on the reaction of 2-pyrazolin-5-ones 1 with o-haloheteroarene-
carbonyl chlorides 2 under the conditions described by Jensen for the C-4 acylation of pyrazolones
(calcium hydroxide, dioxane, reflux) [17] and subsequent ring closure of the resulting 4-heteroaroyl-
pyrazol-5-ols 3 (Scheme 1). Following this approach, we have obtained compounds of type 4 bearing –
amongst others – a pyridine (all positional isomers) [9], quinoline [9], pyridazine [11], pyrimidine
[11], pyrazine [15], thiophene (all positional isomers) [10,11], benzo[b]thiophene [10] and thieno[2,3-
b]thiophene systems [11] as the variable heteroaromatic moiety (‘Het’) condensed to the central
γ-pyranone ring.
Figure 1. Xanthone, xanthione and its heterocyclic analogue amlexanox.
O
O
CH3
S
COOH
NH2
H3C
O
O
N
O
amlexanox
xanthone
(dibenzo-γ-pyrone)
xanthione
(AphthasolTM
)
In continuation of these investigations we present here the synthesis and spectroscopic data of
related congeners 4a,b and 4d-g containing a pyrazole system as the heteroaromatic moiety (‘Het’ =
pyrazole) (Scheme 1), i.e. substituted 1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-ones. Moreover, the
corresponding thiones 5a,b and 5d-g are described. Considering that thio analogues of flavones,
isoflavones, xanthones (= xanthione, Figure 1) and related systems have received considerable
attention due to the importance of such molecules in biology and photochemistry [18], the latter
systems 5 are interesting compounds in their own right as well [19,20].
Scheme 1. Synthesis of compounds 4 and 5.
O
X
R3
R3
N
R3
S
O
R3
O
Cl
Het
Het
Het
N
Het
N
N
+
O
N
R1
N
R1
N
R1
N
O
O
X
OH
R1
5
3
4
1
2

Molecules 2010, 15
6108
2. Results and Discussion
2.1. Chemistry
Synthesis of the target compounds 4 was accomplished via the sequence shown in Scheme 2.
2-Pyrazolin-5-ones 1 are either commercially available or can be easily prepared according to known
methods [21]. Acid chlorides 2, which can be considered as the key synthons in the approach
presented, were prepared as follows: Vilsmaier-Haak formylation [22] of pyrazolones 1a and 1b,
respectively, gave the 5-chloropyrazole-4-carbaldehydes 6, which were oxidized to the corresponding
carboxylic acids 7 by treatment with potassium permanganate [23]. Transformation of acids 7 into the
appropriate acid chlorides 2 was accomplished with thionyl chloride in refluxing toluene [9,11,12].
Compounds 2 were always freshly prepared before reacting them with pyrazolones 1; treatment of
7a,b with dry ethanol led to esters 9a,b [24] (Scheme 2).
Scheme 2. Synthesis of compounds 2–8.
OHC
Cl
R
HOOC
Cl
R
R
3, 4, 5 R1 R3 R3
------------------------------
1
R1
R3
POCl3
DMF
KMnO4
---------------------------------
N
N
N
a
b
c
d
e
f
Ph
Ph
Ph Me
H
H
H
Me
H
a
b
c
d
e
Ph
Ph
Me
PMB*
Bn
H
O
N
N
N
Me
Me
H
Ph
Ph
Ph
Ph Me Me
a: R = H
SOCl2
toluene
6a,b
7a,b
Me Me
PMB
Bn Me
H
H
H
1a,b
Me
b: R = Me
H
g
*PMB = 4-methoxybenzyl
O
O
R3
S
R3
R
R3
R3
R
O
R
R
Lawesson's
reagent
Cl
K2CO3
Ca(OH)2
dioxane
N
N
+
N
N
N
N
N
N
O
DMF
Cl
N
R1
N
N
R1
1
N
N
N
N
O
N
O
Cl
OH
R1
Ph
Ph
Ph
Ph
R1
5
3
4
2a,b
O
R3
Me
R3
Cl
Me
O
O
Ca(OH)2
dioxane
8a: R1 = Me, R3 = Me
8b: R1 = PMB, R3 = H
+
N
N
N
N
O
Cl
N
R1
N
N
R1
N
Ph
Cl
Ph
1c,d
8a,b
2b
EtOOC
Cl
R
EtOH
2a,b
a: R = H
b: R = Me
N
N
Ph
9a,b
Different pyrazolones 1a-e were reacted with acid chlorides 2a,b using calcium hydroxide in
boiling dioxane [17] to afford the 4-pyrazoloylpyrazol-5-ols 3a-g (Scheme 2). However, in two cases
(the reactions of 1c with 2b, and 1d with 2b, respectively) the corresponding compounds of type 3
were not obtained, and instead, the isomeric esters 8a and 8b resulting from O-aroylation of 1c and 1d
were isolated as the major products from the reaction mixtures. Their structures could be easily

Molecules 2010, 15
6109
derived from the 1H-NMR spectra considering the characteristic singlet signal due to pyrazole H-4 at δ
6.04 (8a) and δ 6.30 ppm (8b). Attempts to convert compounds 8 into their corresponding 4-aroyl
congeners 3 failed. Finally, cyclization of intermediates 3 under standard conditions (K2CO3 in DMF)
[25] gave the target tricycles 4a,b and 4d-g in good yields. Treatment of the latter with Lawesson’s
reagent [26-28] in refluxing toluene smoothly afforded the corresponding thiones 5a,b and 5d-g. It
should be mentioned that compounds 4d and 5d have already been described by Sarenko and
coworkers [29]. Finally, the N-7 unsubstituted compounds 4x and 5x were prepared by treatment of
the corresponding N7-PMB-protected congeners 4f and 5f, respectively, with trifluoroacetic acid at
70 ºC [9,12] (Scheme 3).
Scheme 3. Synthesis of compounds 4x and 5x and their possible tautomeric forms.
X
X
X
XH
H
NOE
TFA
N
N
N
H
N
N
N
N
N
N
N
N
N
N
N
N
N
O
O
O
O
Ph
Ph
H
Ph
Ph
6H-form
7H-form
XH-form
4f: X = O
5f: X = S
4x: X = O
5x: X = S
MeO
2.2. NMR Spectroscopic Investigations
The NMR data of compounds 2, 3, 6-8 are given in the Experimental, whereas those of title
compounds 4 and 5 are collected in Tables 2–5. Unequivocal assignment of signals was carried out by
1
the combined application of standard NMR spectroscopic techniques such as H-coupled 13C-NMR
spectra, APT, HMQC, gs-HSQC, gs-HMBC, COSY, TOCSY, NOESY and NOE-difference
spectroscopy [30]. Moreover, in a few cases experiments with selective excitation (DANTE) of certain
1H-resonances were performed, such as long-range INEPT [31] and 2D(δ,J) long-range INEPT [32],
the latter experiments were indispensable for the unambiguous mapping of long-range 13C,1H coupling
constants. Reliable and unambiguously assigned chemical shift data such as those presented here can
be considered as important reference material for NMR prediction programs, such as CSEARCH
[33]/NMRPREDICT [34] and ACD/C + H predictor [35] – programs which have become very popular
in the last few years, particularly for predicting 13C-NMR chemical shifts.
4-Aroylpyrazol-5-ols 3 in each case contain two different pyrazole units which exhibit
characteristic differences regarding their chemical shift data. The 5-OH group in the hydroxypyrazole
moiety leads to a strong polarization of the C4−C5 bond resulting in small chemical shifts for pyrazole
C-4 (103−106 ppm) and large ones for pyrazole C-5 (159−161 ppm). These differences are
significantly smaller in the 5-chloropyrazole unit with δ pyrazole C-4 having 117−119 ppm and
pyrazole C-5 127−131 ppm. In congeners carrying phenyl substituents at both pyrazole N-1’s
(compounds 3a-d) an explicit difference regarding the resonances due to Ph C-2,6 is quite obvious (δ
~121 ppm in the 1-Ph-pyrazol-5-ol unit, δ ~125.5 ppm in the 1-Ph-5-Cl-pyrazole unit). Moreover, also
the 15N-NMR chemical shifts in the mentioned pyrazole moieties differ markedly, both nitrogen atoms
of the hydroxypyrazole system (for instance 3a: N-1 −185.2 ppm, N-2 −97.9 ppm) show distinctly
smaller chemical shifts than the corresponding ones in the chloropyrazole system (N-1 −159.9 ppm, N-

Molecules 2010, 15
6110
2 −72.4 ppm). The C=O resonance in compounds 3 is located in the range from 181−184 ppm. In
Figure 2, 1H, 13C and 15N-NMR chemical shift data are presented for 3a which can be considered as a
typical example.
Figure 2. 1H- (in italics), 13C- and 15N-NMR (in bold) chemical shifts in 3a, 4a and 5a (δ,
ppm, in CDCl3).
8.02
H8.26
117.9
8.39H
138.1
8.22 H
136.7
H
138.5
O
108.8 O
S 192.1
169.7
103.7
117.8
141.1
4
3
-97.9
5
181.5
4a
7a
-72.4
N
3a
N
-86.8
2
-84.5
6
N
N
N
N
8a
8
-185.2
-159.9
125.5
129.3
1
7
N
N
-186.8
-187.6
121.3
129.7
N
137.2
N 151.3
N
137.2
N145.5
O
O
OH
Cl
121.1
136.6
136.6
159.9
7.89
130.5
7.57
121.3
129.6
129.2
7.82
7.55
7.84
7.57
7.50
129.5
127.2
7.35
7.54-7.58
128.3
7.44
128.3
7.46
3a (CDCl3)
5a (CDCl3)
4a (CDCl3)
In Figure 2, the chemical shift data for the corresponding tricycles 4a and 5a are also depicted,
which − exemplarily – permit one to follow the changes when switching from the central pyran-4-one
1
13
(4a) to a pyran-4-thione (5a) system. The transformation 4a → 5a leaves the H- and
C-NMR
chemical shifts due to the phenyl ring nearly unchanged; δ (N-1), δ (N-2) and δ (C-3) are also only
slightly affected. However, in 4a a pronounced ‘push-pull situation’ is on hand which leads to a strong
polarization of the pyrane C=C bond resulting in a large chemical shift for C7a/C8a (δ 151.3 ppm) and
a small for C3a/C4a (δ 108.8 ppm). In 5a this effect is much less pronounced leading to an upfield
shift for C7a/C8a (δ 145.5 ppm) and a marked downfield shift for C3a/C4a (δ 117.8 ppm) compared to
the appropriate shifts in 4a. Expectedly, C-4 suffers a distinct downfield shift (169.7 ppm → 192.1
ppm) when switching from 4a to 5a, the difference of 22.4 ppm is comparable with corresponding
values found in related systems [36].
Whereas assignment of signals in most cases is easy, the discrimination of signals due to N1-phenyl
and N7-phenyl in ‘asymmetric’ compounds 4b and 5b is not trivial. Ultimately, this assignment is
possible considering the correlations found in the 15N,1H-HMBC spectra. Thus, for instance, in
15
compound 5b the singlet signal due to H-5 (δ 8.32 ppm) exhibits a correlation to the N signal with
δ -188.0 ppm, which consecutively must be that of N-7. The latter is also connected to the Ph H-2,6
resonance at δ 7.82 ppm, which accordingly has to be part of the N-7-phenyl system and thus can be
unambiguously distinguished from Ph H-2,6 of the N1-phenyl moiety (δ 7.81 ppm). On basis of COSY
(TOCSY), HSQC and HMBC experiments then the unequivocal assignment of all proton and carbon
signals due to N1-Ph and N7-Ph is possible.
Compounds 4x and 5x, bearing no substituent at N-7, are interesting compounds capable of
prototropic tautomerism with the 7H-, 6H- and XH-forms being possible (Scheme 3). The presence of
XH-forms is improbable considering the chemical shifts for C-4 (4x: 170.5 ppm; 5x: 193.5 ppm)
which perfectly match those for δ (C-4) of all other N-7 substituted congeners of type 4 and 5, with the
latter having no possibility for the formation XH-isomers. As irradiation of the resonance due to the
pyrazole NH proton gives the H-5 singlet a strong NOE (Scheme 3) a significant contribution of the
6H-form to the overall tautomeric composition is evident. This assumption is supported by 13C

Molecules 2010, 15
6111
chemical shift data and by the size of certain 13C,1H coupling constants. Hence, in 5x 2J(C4a,H5) (7.8
2
Hz) is somewhat smaller than J(C3a,H3) (9.5 Hz) on the opposite site of the molecule what can be
3
explained by lone-pair effects according to lit. [38]. Also J(C8a,H3) = 4.9 Hz markedly differs from
the corresponding coupling constant 3J(C7a,H5) = 8.5 Hz. Moreover, δ C-7a (155.0 ppm) is larger than
δ C-8a (147.6 ppm) and, conversely, δ C-5 (130.2 ppm) is significantly smaller than δ C-3 (137.7
ppm). Both phenomena can smoothly be explained by a strong contribution of the 6H-form in which
C-5 is of ‘pyrazole C-5 type’ and C-7a of ‘pyrazole C-3 type’ – just opposite as for the 7H-form and
for ‘fixed’ forms with a substituent attached to N-7. For comparison, δ (C-3) in 3-methoxy-1-
phenylpyrazole (166.7 ppm) is markedly larger than δ (C-5) in 5-methoxy-1-phenylpyrazole (155.5
ppm), whereas – vice versa – δ (C-5) in 3-methoxy-1-phenylpyrazole (129.7 ppm) is significantly
smaller than δ (C-3) in 5-methoxy-1-phenylypyrazole (139.6 ppm) [37-39].
Lastly, the spectra of esters 8a and 8b are characterized by the occurence of a pyrazole C−H moiety
with typically small chemical shifts for pyrazole H-4 (8a: 6.04 ppm, 8b: 6.30 ppm) and pyrazole C-4
(8a: 93.9 ppm, 8b: 94.9 ppm). Compared to the corresponding signals in 4-aroylpyrazol-5-ols 3
(~160 ppm) the resonance of pyrazole C-5 in the O-substituted pyrazole units of compounds 8 are
significantly shifted upfield (8a: 144.6 ppm, 8b: 144.3 ppm). Furthermore, the C=O resonances of
compounds 8 exhibit remarkably small chemical shifts typical for ester carbonyl C-atoms of aryl esters
(8a: 157.3 ppm, 8b: 157.2 ppm).
3. Experimental
3.1. General
Melting points were determined on a Reichert–Kofler hot-stage microscope and are uncorrected.
Mass spectra were obtained on a Shimadzu QP 1000 instrument (EI, 70 eV), a Finnigan MAT 8230
instrument (EI, 70 eV, HRMS), and a Finnigan MAT 900S instrument (ESI, 4 kV, MeOH-
acetonitrile). IR spectra (KBr unless otherwise stated) were recorded on a Perkin-Elmer FT-IR 1605
spectrophotometer. Elemental analyses (C, H, N and S) were performed at the Microanalytical
Laboratory, University of Vienna, and were in good agreement (±0.4%) with the calculated values. 1H-
13
and C-NMR spectra were recorded on a Varian UnityPlus 300 spectrometer at 28 ºC (299.95 MHz
1
13
1
for H, 75.43 MHz for C) or on a Bruker Avance 500 spectrometer at 293 K (500.13 MHz for H,
13
125.77 MHz for C). The center of the solvent signal was used as an internal standard, which was
related to TMS with δ 7.26 ppm (1H, CDCl3), δ 2.49 ppm (1H, DMSO-d6), δ 77.0 ppm (13C, CDCl3)
and δ 39.5 ppm (13C, DMSO-d6). N-NMR spectra (50.68 MHz) were obtained on a Bruker Avance
15
500 spectrometer with a ‘directly’ detecting broadband observe probe (BBFO) and were referenced
1
against external nitromethane. The digital resolution was 0.25 Hz/data point in the H spectra and 0.4
Hz/data point in the 13C-NMR spectra. Systematic names were generated with ACD/Name [40]
according to the IUPAC recommendations and were checked manually [41]. For chromatographic
separations, Kieselgel 60 (70–230 mesh, Merck) was used.

Molecules 2010, 15
6112
3.2. Synthetic procedures
3.2.1. General procedure for the synthesis of the carbaldehydes 6a and 6b
Under anhydrous conditions, POCl3 (53.65 g, 32.5 mL, 350 mmol) was carefully added dropwise to
dry DMF (11.70 g, 12.3 mL, 160 mmol) under cooling. Then pyrazolone 1 (50 mmol) was added and
the mixture was heated to reflux for 2 hours. The reaction mixture was subsequently cooled to room
temperature and the darkly coloured solution was poured onto ice water (approximately 300 mL) while
stirring. After 30 minutes the precipitate formed was filtered off, washed with H2O and dried.
5-Chloro-1-phenyl-1H-pyrazole-4-carbaldehyde (6a). Starting from 1-phenyl-2-pyrazolin-5-one
(1a, 8.01 g, 50 mmol) 8.69 g (84%) of compound 6a were obtained as brownish crystals; m.p. 68 ºC
1
(lit. [42] m.p. 70 ºC); H-NMR (500 MHz, CDCl3): δ (ppm) 9.92 (s, 1H, CHO), 8.14 (s, 1H, H-3),
1
7.46–7.57 (m, 5H, Ph-H); 13C-NMR (125 MHz, CDCl3): δ (ppm) 182.9 (CHO, J = 177.9 Hz,
3J (CHO,H-3) = 0.6 Hz), 140.9 (C-3, 1J (C-3,H-3) = 193.1 Hz, 3J(C-3,CHO) = 3.7 Hz), 136.8 (Ph C-1),
132.4 (C-5, 3J(C-5,H-3) = 5.9 Hz), 129.4 (Ph C-4), 129.3 (Ph C-3,5), 125.1 (Ph C-2,6), 120.1 (C-4, 2J
2
15
(C-4,H-3) = 9.5 Hz, J(C-4,CHO) = 25.2 Hz); N-NMR (50 MHz, CDCl3): δ (ppm) −161.5 (N-1),
−70.3 (N-2); MS m/z (%): 206/208 (M+, 89/30), 205/207 (M+-1, 93/38), 167 (33), 149 (100), 77 (75),
57 (46), 51 (58), 43 (36), 41 (42).
5-Chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbaldehyde (6b). Starting from 3-methyl-1-phenyl-2-
pyrazolin-5-one (1b, 8.71 g, 50 mmol) 9.05 g (82%) of compound 6b were obtained as brownish
1
crystals; m.p. 146 ºC (lit. [43] m.p. 146–147 ºC); H-NMR (500 MHz, CDCl3): δ (ppm) 9.96 (s, 1H,
CHO), 7.53 (m, 2H, Ph H-2,6), 7.51 (m, 2H, Ph H-3,5), 7.46 (m, 1H, Ph H-4), 2.53 (s, 3H, Me);
13C-NMR (125 MHz, CDCl3): δ (ppm) 183.8 (CHO, 1J = 176.2 Hz), 151.7 (C-3, 2J(C-3,Me) = 7.0 Hz,
3J(C-3,CHO) = 4.6 Hz), 136.9 (Ph C-1), 133.4 (C-5), 129.2 (Ph C-3,5), 129.1 (Ph C-4), 125.1 (Ph C-
15
2,6), 117.3 (C-4, 2J(C-4,CHO) = 24.3 Hz, 3J(C-4,Me) = 2.5 Hz), 13.8 (Me, 1J = 129.4 Hz); N-NMR
(50 MHz, CDCl3): −168.1 (N-1), −76.1 (N-2).
3.2.2. Preparation of 5-chloro-1-phenyl-1H-pyrazole-4-carboxylic acid (7a). To a solution of 6a
(1.03 g, 5 mmol) in a mixture of H2O/t-butanol 1:1 (15 mL) 1.11 g (7 mmol) KMnO4 in H2O (20 mL)
was added dropwise over 3 h while stirring at 70–80 ºC. Then an aqueous solution of 10% KOH was
added while stirring until the solution turned alkaline. The mixture was filtered, then the filtrate was
acidified with concentrated hydrochloric acid to pH 2. The precipitated solid was filtered off, washed
with water and dried. Yield: 970 mg (88%) of colorless crystals; m.p. 188 ºC (lit. [44] m.p. 187–188
ºC); 1H-NMR (300 MHz, DMSO-d6): δ (ppm) 12.97 (s, 1H, OH), 8.16 (s, 1H, H-3), 7.52–7.60 (m, 5H,
13
1
Ph-H); C-NMR (75 MHz, DMSO-d6): δ (ppm) 162.3 (C=O), 142.4 (C-3, J(C-3,H-3) = 193.5 Hz),
3
137.2 (Ph-C-1), 130.2 (C-5, J(C-5,H-3) = 5.8 Hz), 129.3 (Ph C-3,4,5), 125.7 (Ph C-2,6), 112.3 (C-4,
2J(C-4,H-3) = 8.9 Hz); N-NMR (50 MHz, DMSO-d6): δ (ppm) −160.8 (N-1), −70.2 (N-2). MS m/z
15
(%): 222/224 (M+, 83/27), 205 (32), 104 (19), 77 (100), 51 (92), 50 (28), 45 (26).

Molecules 2010, 15
6113
3.2.3. Preparation of 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid (7b)
The title compound was prepared according to a related procedure given in [23].
3.2.4. General procedure for the synthesis of the acid chlorides 2a and 2b
A suspension of the accordant carboxylic acid 7 (2 mmol) in toluene (10 mL), excess SOCl2 (10
mL) and 1 droplet of DMF was refluxed for 3 h. Then toluene and excess SOCl2 were distilled off.
More toluene was added and the solvent was distilled off again. The remaining acid chloride was
used immediately.
5-Chloro-1-phenyl-1H-pyrazole-4-carbonyl chloride (2a). Starting from 7a (445 mg, 2 mmol) 470 mg
1
(98%) of compound 2a were obtained as yellowish crystals; m.p. 134 ºC; H-NMR (500 MHz,
CDCl3): δ (ppm) 8.25 (s, 1H, H-3), 7.54 (m, 5H, Ph-H); 13C-NMR (125 MHz, CDCl3): δ (ppm) 158.3
(C=O), 144.9 (C-3, 1J(C-3,H-3) = 196.2 Hz), 136.8 (Ph C-1), 132.2 (C-5, 3J(C-5,H-3) = 4.5 Hz), 129.8
(Ph C-4), 129.4 (Ph C-3,5), 125.3 (Ph C-2,6), 116.1 (C-4, 2J(C-4,H-3) = 8.8 Hz); 15N-NMR (50 MHz,
CDCl3): δ (ppm) −157.7 (N-1), −71.0 (N-2); MS m/z (%): 240/242/244 (M+, 12/8/1), 205 (100), 77
(51), 51 (36). HRMS Calcd. for C10H6Cl2N2O: 239.9857. Found: 239.9851.
5-Chloro-3-methyl-1-phenyl-1H-pyrazole-4-carbonyl chloride (2b). Starting from 7b (473 mg,
2 mmol) 481 mg (92%) of compound 2b were obtained as a colorless powder; m.p. 97 ºC (lit. [45] m.p.
87 ºC); 1H-NMR (125 MHz, CDCl3): δ (ppm) 7.52 (m, 5H, Ph-H), 2.57 (s, 3H, 3-Me); 13C-NMR (125
2
MHz, CDCl3): δ (ppm) 158.4 (COCl), 151.9 (C-3, J(C-3,3-Me) = 7.1 Hz), 136.0 (Ph C-1), 132.2
3
(C-5), 128.6 (Ph C-4), 128.3 (Ph C-3,5), 124.6 (Ph C-2,6), 113.2 (C-4, J(C-4,3-Me) = 2.5 Hz), 14.5
1
(Me, J = 129.9 Hz); 15N-NMR (50 MHz, CDCl3): δ (ppm) −164.9 (N-1), −76.3 (N-2); IR: 1740
(C=O) cm-1; MS m/z (%): 254/256/258 (M+, 8/5/1), 219 (100), 155 (19), 91 (16), 77 (34), 51 (24).
3.2.5. Acylation of Pyrazolones: General procedure for the synthesis of 3a-g and 8a-b
A solution of the appropriate acid chloride 2 (5 mmol) in dry 1,4-dioxane (5 mL) was added
dropwise to a suspension of pyrazolone (1a-e, 5 mmol) and Ca(OH)2 (10 mmol) in dry 1,4-dioxane
(5 mL). The reaction mixture was heated to reflux for 3 h under anhydrous conditions. After cooling to
room temperature the mixture was treated with 2 N HCl (20 mL), stirred for 30 min and afterwards
H2O (20 mL) was added. Then the products were filtered off, washed with H2O and recrystallized.
Spectroscopic and analytical data of 3a-g and 8a-b are summarized in Table 1.
(5-Chloro-1-phenyl-1H-pyrazol-4-yl)(5-hydroxy-1-phenyl-1H-pyrazol-4-yl)methanone (3a). Starting
from pyrazolone 1a (801 mg, 5 mmol) and acid chloride 2a (1.21 g, 5 mmol) 1.58 g (86%) of
compound 3a were obtained as yellowish crystals of m.p. 207 ºC (EtOH).
(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)(5-hydroxy-1-phenyl-1H-pyrazol-4-yl)methanone (3b).
Starting from pyrazolone 1a (801 mg, 5 mmol) and acid chloride 2b (1.28 g, 5 mmol) 1.04 g (55%) of
compound 3b were obtained as colorless crystals of m.p. 153 ºC (EtOH).

Molecules 2010, 15
6114
(5-Chloro-1-phenyl-1H-pyrazol-4-yl)(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methanone (3c).
Starting from pyrazolone 1b (871 mg, 5 mmol) and acid chloride 2a (1.21 g, 5 mmol) 1.37 g (72%) of
compound 3c were obtained as brownish crystals of m.p. 168 ºC (EtOH).
(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)
methan-one (3d). Starting from pyrazolone 1b (871 mg, 5 mmol) and acid chloride 2b (1.28 g, 5
mmol) 943 mg (48%) of compound 3d were obtained as colorless crystals of m.p. 217–219 ºC (EtOH)
(lit. [29] m.p. 219–220 ºC).
(5-Chloro-1-phenyl-1H-pyrazol-4-yl)(5-hydroxy-1,3-dimethyl-1H-pyrazol-4-yl)methanone (3e). From
pyrazolone 1c (561 mg, 5 mmol) and acid chloride 2a (1.21 g, 5 mmol) 1.03 g (65%) of compound 3e
were obtained as colorless crystals of m.p. 184 ºC (EtOH).
(5-Chloro-1-phenyl-1H-pyrazol-4-yl)[5-hydroxy-1-(4-methoxybenzyl)-1H-pyrazol-4-yl]methanone
(3f). Starting from pyrazolone 1d (1.02 g, 5 mmol) and acid chloride 2a (1.21 g, 5 mmol) 1.40 g (68%)
of compound 3f were obtained as colorless crystals of m.p. 166–167 ºC (EtOH).
(1-Benzyl-5-hydroxy-3-methyl-1H-pyrazol-4-yl)(5-chloro-1-phenyl-1H-pyrazol-4-yl)methanone (3g).
Starting from pyrazolone 1e (941 mg, 5 mmol) and acid chloride 2a (1.21 g, 5 mmol) 1.92 g (98%) of
compound 3g were obtained as orange crystals of m.p. 119 ºC (EtOH).
1,3-Dimethyl-1H-pyrazol-5-yl 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxylate (8a). Starting
from pyrazolone 1c (561 mg, 5 mmol) and acid chloride 2b (1.28 g, 5 mmol) 810 mg (49%) of
compound 8a were obtained as colorless crystals of m.p. 146 ºC (EtOH).
1-(4-Methoxybenzyl)-1H-pyrazol-5-yl 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxylate (8b).
Starting from pyrazolone 1d (1.021 g, 5 mmol) and acid chloride 2b (1.28 g, 5 mmol) 1.08 g (51%) of
compound 8b were obtained as colorless crystals of m.p. 116 ºC (EtOH).
Table 1. Spectroscopic and analytical data of compounds 3a-g and 8a-b.
Entry
Structure
Spectroscopic and analytical data
1H-NMR (300 MHz, CDCl3): δ (ppm) 8.26 (s, 1H, H-3’), 8.02 (s, 1H, H-3), 7.89
(m, 2H, N1-Ph H-2,6), 7.54–7.58 (3H, N1’-Ph H-3,4,5), 7.57 (m, 2H, N1’-Ph
H-2,6), 7.50 (m, 2H, N1-Ph H-3,5), 7.35 (m, 1H, N1-Ph H-4), 6.0–8.5 (very
broad s, 1H, OH); 13C-NMR (75 MHz, CDCl3): δ (ppm) 181.5 (C=O), 159.9 (C-
H
3
H
3'
O
3
1
5, J(C-5,H-3) = 4.9 Hz), 141.1 (C-3’, J(C-3’,H-3’) = 190.7 Hz), 138.5 (C-3,
1J(C-3,H-3) = 189.3 Hz), 137.2 (N1-Ph C-1 and N-1’-Ph C-1), 130.5 (C-5’,
3J(C-5’,H-3’) = 5.9 Hz), 129.5 (N1’-Ph C-4), 129.3 (N1’-Ph C-3,5), 129.2 (N1-
Ph C-3,5), 127.2 (N1-Ph C-4), 125.5 (N1’-Ph C-2,6), 121.1 (N1-Ph C-2,6),
117.9 (C-4’, 2J(C-4’,H-3’) = 10.3 Hz), 103.7 (C-4, 2J(C-4,H-3) = 11.1 Hz); 15N-
NMR (50 MHz, CDCl3): δ (ppm) −185.2 (N-1), −159.9 (N-1’), −97.9 (N-2),
−72.4 (N-2’); IR: 1656 (C=O) cm-1; MS m/z (%): 364/266 (M+, 23/8), 329 (38),
186 (100), 91 (18), 77 (52), 51 (22). Calcd. for C19H13ClN4O2 (364.79): C,
62.56; H, 3.59; N, 15.36. Found: C, 62.39; H, 3.50; N, 15.16.
2
2'
N
4
5
4'
5'
N
N
N
3a
1
1'
OH
Cl

Molecules 2010, 15
6115
Table 1. Cont.
1H-NMR (500 MHz, CDCl3): δ (ppm) 10.18 (broad s, 1H, OH), 7.92 (s, 1H, H-
3), 7.89 (m, 2H, N1-Ph H-2,6), 7.58 (m, 2H, N1’-Ph H-2,6), 7.53 (m, 2H, N1’-
Ph H-3,5), 7.49 (m, 2H, N1-Ph H-3,5), 7.48 (1H, N1’-Ph H-4), 7.34 (m, 1H,
N1-Ph H-4), 2.50 (s, 3H, 3’-Me); 13C-NMR (125 MHz, CDCl3): δ (ppm) 183.0
H
3
CH3
3'
O
3
2
(C=O), 160.0 (C-5, J(C-5,H-3) = 4.7 Hz), 150.5 (C-3’, J(C-3’,3’-Me) = 6.9
1
Hz), 140.1 (C-3, J(C-3,H-3) = 191.1 Hz), 137.3 (N1’-Ph C-1), 137.2 (N1-Ph
2
N
2'
4
4'
5'
N
C-1), 129.2 (N1’-Ph C-3,5), 129.15 (N1-Ph C-3,5), 129.05 (N1’-Ph C-4),
127.6 (C-5’), 127.0 (N1-Ph C-4), 125.4 (N1’-Ph C-2,6), 120.9 (N1-Ph C-2,6),
5
N
N
3b
1
1'
OH
Cl
3
2
117.4 (C-4’, J(C-4’,3’-Me) = 2.8 Hz), 104.2 (C-4, J(C-4,H-3) = 10.6 Hz),
13.8 (3’-Me, 1J = 129.1 Hz); 15N-NMR (50 MHz, CDCl3): δ (ppm) −186.0 (N-
1), −167.8 (N-1’), −97.3 (N-2), −75.8 (N-2’); IR: 1559 (C=O) cm-1; MS m/z
(%): 378/380 (M+, 12/4), 343 (45), 219 (11), 186 (100), 118 (12), 91 (15), 77
(43), 51 (16). Calcd. for C20H15ClN4O2 (378.81): C, 63.41; H, 3.99; N, 14.79.
Found: C, 63.24; H, 3.81; N, 14.74.
1H-NMR (500 MHz, CDCl3): δ (ppm) 8.01 (s, 1H, H-3’), 7.87 (m, 2H, N1-Ph
H-2,6), 7.60 (m, 2H, N1’-Ph H-2,6), 7.55 (m, 2H, N1’-Ph H-3,5), 7.52 (m, 1H,
N1’-Ph H-4), 7.48 (m, 2H, N1-Ph H-3,5), 7.32 (m, N1-Ph H-4), 2.39 (s, 3H, 3-
Me), OH not found; 13C-NMR (125 MHz, CDCl3): δ (ppm) 182.9 (C=O),
161.0 (C-5), 147.3 (C-3, 2J(C-3,3-Me) = 6.8 Hz), 140.8 (C-3’, 1J(C-3’,H-3’) =
192.0 Hz), 137.3 (N1’-Ph C-1), 137.1 (N1-Ph C-1), 129.3 (N1’-Ph C-3,4,5),
129.1 (N1-Ph C-3,5), 129.0 (C-5’, 3J(C-5’,H-3’) = 5.6 Hz), 126.9 (N1-Ph C-4),
CH3
3
H
3'
O
2
N
2'
4
5
4'
5'
N
N
N
3c
1
1'
2
OH
Cl
125.4 (N1’-Ph C-2,6), 120.9 (N1-Ph C-2,6), 118.4 (C-4’, J(C-4’,H-3’) = 10.1
3
1
Hz), 104.4 (C-4, J(C-4,3-Me) = 2.7 Hz), 15.6 (3-Me, J = 128.8 Hz); 15N-
NMR (50 MHz, CDCl3): δ (ppm) −190.3 (N-1), −161.7 (N-1’), −100.8 (N-2),
−74.2 (N-2’); IR: 1619 (C=O) cm-1; MS m/z (%): 378/380 (M+, 8/3), 342 (48),
200 (100), 91 (37), 77 (58), 51 (25). Calcd. for C20H15ClN4O2 (378.81): C,
63.41; H, 3.99; N, 14.79. Found: C, 63.71; H, 3.91; N, 14.69.
1H-NMR (500 MHz, CDCl3): δ (ppm) 9.20 (broad s, 1H, OH), 7.87 (m, 2H,
N1-Ph H-2,6), 7.56 (m, 2H, N1’-Ph H-2,6), 7.52 (m, 2H, N1’-Ph H-3,5), 7.47
(m, 2H, N1-Ph H-3,5), 7.47 (m, 1H, N1’-Ph H-4), 7.31 (m, 1H, N1-Ph H-4),
2.41 (s, 3H, 3’-Me), 2.23 (s, 3H, 3-Me); 13C-NMR (125 MHz, CDCl3): δ (ppm)
CH3
3
CH3
3'
O
2
183.8 (C=O), 160.8 (C-5), 148.8 (C-3’, J(C-3’,3’-Me) = 6.8 Hz), 148.1 (C-3,
2J(C-3,3-Me) = 6.7 Hz), 137.4 (N1’-Ph C-1), 137.1 (N1-Ph C-1), 129.2 (N1’-
2
2'
N
4
5
4'
5'
N
Ph C-3,5), 129.1 (N1-Ph C-3,5), 128.9 (N1’-Ph C-4), 126.8 (N1-Ph C-4),
N
1
N
3d
3
126.7 (C-5’), 125.2 (N1’-Ph C-2,6), 120.7 (N1-Ph C-2,6), 117.8 (C-4’, J(C-
1'
OH
Cl
3
1
4’,3’-Me) = 3.0 Hz), 105.5 (C-4, J(C-4,3-Me) = 2.8 Hz), 13.9 (3-Me, J =
129.0 Hz), 13.0 (3’-Me, 1J = 128.9 Hz); 15N-NMR (50 MHz, CDCl3): δ (ppm)
−190.3 (N-1), −168.8 (N-1’), −100.0 (N-2), −76.6 (N-2’); MS m/z (%):
392/394 (M+, 5/2), 356 (39), 219 (10), 200 (100), 132 (13), 91 (31), 77 (40),
67 (12), 51 (15). Calcd. for C21H17ClN4O2 (392.84): C, 64.21; H, 4.36; N,
14.26. Found: C, 64.04; H, 4.18; N, 14.21.
1H-NMR (300 MHz, CDCl3): δ (ppm) 10.35 (broad s, 1H, OH), 7.94 (s, 1H, H-
3’), 7.44–7.59 (m, 5H, N1’-Ph), 3.62 (s, 3H, N1-Me), 2.27 (s, 3H, 3-Me); 13C-
NMR (75 MHz, CDCl3): δ (ppm) 183.4 (C=O), 160.2 (C-5, J(C-5,N1-Me) =
3
CH3
3
H
3'
O
2
1
2.3 Hz), 146.2 (C-3, J(C-3,3-Me) = 6.9 Hz), 140.6 (C-3’, J(C-3’,H-3’) =
3
191.7 Hz), 137.4 (N1’-Ph C-1), 129.2 (N1’-Ph C-3,4,5), 128.6 (C-5’, J(C-
5’,H-3’) = 5.7 Hz), 125.3 (N1’-Ph C-2,6), 119.0 (C-4’, J(C-4’,H-3’) = 10.1
2
2'
N
4
5
4'
5'
N
2
N
3e
N
3
1
Hz), 103.2 (C-4, J(C-4,3-Me) = 2.7 Hz), 32.5 (N1-Me, J = 140.9 Hz), 15.2
1
1'
OH
Cl
(3-Me, J = 128.6 Hz); 15N-NMR (50 MHz, CDCl3): δ (ppm) −207.9 (N-1),
1
H3C
−162.2 (N-1’), −100.5 (N-2), −74.7 (N-2’); IR: 1636 (C=O) cm-1;MS m/z (%):
316/318 (M+, 11/4), 281 (26), 138 (100), 77 (21), 51 (17). Calcd. for
C15H13ClN4O2 (316.74): C, 56.88; H, 4.14; N, 17.69. Found: C, 57.12; H, 3.97;
N, 17.61.

Molecules 2010, 15
6116
Table 1. Cont.
1H-NMR (300 MHz, CDCl3): δ (ppm) 8.18 (s, 1H, H-3’), 7.30–8.00 (very
broad s, 1H, OH), 7.82 (broad, s, 1H, H-3), 7.55 (m, 2H, N1’-Ph H-2,6), 7.52
(m, 3H, N1’-Ph H-3,4,5), 7.31 (m, 2H, CH2-Ph H-2,6), 6.88 (CH2-Ph H-3,-5),
5.13 (broad s, 2H, CH2), 3.79 (s, 3H, OMe); 13C-NMR (75 MHz, CDCl3): δ
(ppm) 181.7 (C=O), 159.5 (CH2-Ph C-4), 159.0 (C-5), 141.1 (C-3’, 1J(C-3’,H-
H
3
H
3'
O
2
N
4
2'
4'
5'
N
5
N
N
1
3’) = 190.7 Hz), 137.9 (C-3, J(C-3,H-3) = 188.8 Hz), 137.3 (N1’-Ph C-1),
1
1'
OH
Cl
3f
130.3 (C-5’), 129.6 (CH2-Ph C-2,6), 129.4 (N1’-Ph C-4), 129.2 (N1’-Ph C-
3,5), 127.5 (CH2-Ph C-1), 125.5 (N1’-Ph C-2,-6), 118.2 (C-4’, 2J(C-4’,H-3’) =
1
10.0 Hz), 114.2 (CH2-Ph C3,5), 103.1 (C-4), 55.3 (OMe, J = 143.9 Hz), 49.8
1
(CH2, J = 140.6 Hz); 15N-NMR (50 MHz, CDCl3): δ (ppm) −189.2 (N-1),
−160.3 (N-1’), −98.3 (N-2), −73.1 (N-2’); IR: 1621 (C=O) cm-1;MS m/z (%):
408/410 (M+, 7/2), 373 (25), 121 (100), 77 (23). Calcd. for C21H17ClN4O3
(408.84): C, 61.69; H, 4.19; N, 13.70. Found: C, 61.47; H, 4.13, N, 13.55.
1H-NMR (300 MHz, CDCl3): δ (ppm) 7.70–8.20 (broad s, 1H, OH), 7.96 (s,
1H, H-3’), 7.58 (m, 2H, N1’-Ph H-2,6), 7.53 (m, 2H, N1’-Ph H-3,5), 7.48 (m,
1H, N1’-Ph H-4), 7.28–7.38 (m, 5H, CH2-Ph), 5.12 (s, 2H, CH2), 2.28 (s, 3H,
OMe
CH3
3
H
3'
O
3
3-Me); 13C-NMR (75 MHz, CDCl3): δ (ppm) 183.3 (C=O), 160.3 (C-5, J(C-
5,CH2) = 2.4 Hz), 146.6 (C-3, 2J(C-3,3-Me) = 7.0 Hz), 140.7 (C-3’, 1J(C-3’,H-
3’) = 192.0 Hz), 137.4 (N1’-Ph C-1), 135.5 (CH2-Ph C-1), 129.2 (N1’-Ph C-
3,4,5), 128.7 (CH2-Ph C-3,5 and C-5’, 3J(C-5’,H-3’) = 5.7 Hz), 128.0 (CH2-Ph
2
2'
N
4
5
4'
5'
N
N
N
1
1'
OH
Cl
3g
2
C-2,4,6), 125.3 (N1’-Ph C-2,6), 118.9 (C-4’, J(C-4’,H-3’) = 10.1 Hz), 103.4
3
1
1
(C-4, J(C-4,3-Me) = 2.6 Hz), 49.8 (CH2, J = 140.2 Hz), 15.4 (3-Me, J =
128.6 Hz); 15N-NMR (50 MHz, CDCl3): δ (ppm) −196.4 (N-1), −162.1 (N-1’),
−101.1 (N-2), −74.7 (N-2’); IR: 1633 (C=O) cm-1; MS m/z (%): 392/394 (M+,
8/3), 356 (91), 91 (100), 77 (25), 51 (18). Calcd. for C21H17ClN4O2 (392.84):
C, 64.21; H, 4.36; N, 14.26. Found: C, 64.13; H, 4.27; N, 14.11.
1H-NMR (300 MHz, CDCl3): δ (ppm) 7.52 (m, 5H, Ph-H), 6.04 (s, 1H, H-4),
3.74 (s, 3H, N-Me), 2.59 (s, 3H, 3’-Me), 2.25 (s, 3H, 3-Me); 13C-NMR (75Hz,
CDCl3): δ (ppm) 157.3 (C=O), 153.1 (C-3’, J(C-3’,3’-Me) = 6.9 Hz), 147.2
H3C
2
4
5
3
O
2
2
3
CH3
3'
(C-3, J(C-3,3-Me) = 6.7 Hz, J(C-3,H-4) = 4.3 Hz), 144.6 (C-5, J(C-5,N-
2
2
N
CH3) = 2.2 Hz, J(C 5,H-4) = 4.4 Hz), 137.2 (Ph-C-1), 132.2 (C-5’), 129.3
O
N
4'
5'
3
2'
N
(Ph-C-4), 129.2 (Ph-C-3,5), 125.5 (Ph-C-2,-6), 108.3 (C-4’, J(C-4’,3’-Me) =
1
8a
2.7 Hz), 93.9 (C-4, 1J(C-4,H-4) = 181.2 Hz, 3J(C-4,3-Me) = 3.5 Hz), 14.8 (3’-
Me, 1J = 129.5Hz), 14.2 (3-Me, 1J = 127.5 Hz); 15N-NMR (50 MHz, CDCl3): δ
(ppm) −202.2 (N-1), −165.8 (N-1’), −98.9 (N-2), −75.7 (N-2’); IR: 1745
(C=O) cm-1; MS m/z (%): 330 (M+, 0.1), 219 (100), 77 (42), 51 (19). Calcd. for
C16H15ClN4O2 (330.77): C, 58.10; H, 4.57; N, 16.94. Found: C, 58.14; H, 4.37;
N, 16.90.
CH3
N
1'
Cl
1H-NMR (300 MHz, CDCl3): δ (ppm) 7.53 (d, 1H, H-3, J(H3,H4) = 2.1 Hz),
3
7.52 (m, 5H, N1’-Ph), 7.12 (m, 2H, CH2-Ph H-2,6), 6.82 (m, 2H, CH2-Ph H-
3,5), 6.30 (d, 1H, H-4, 3J(H4,H3) = 2.1 Hz), 5.28 (s, 2H, CH2), 3.75 (s, 3H, O-
Me), 2.52 (s, 3H, 3’-Me); 13C-NMR (75 MHz, CDCl3): δ (ppm) 159.2 (CH2-Ph
H
3
2
4
5
O
C4), 157.2 (C=O), 153.2 (C-3’, J(C-3’,3’-Me) = 7.0 Hz), 144.3 (C-5), 138.7
CH3
3'
1
2
(C-3, J(C-3,H-3) = 187.6 Hz, J(C-3,H-4) = 4.8 Hz), 137.2 (N1’-Ph C-1),
132.2 (C-5’), 129.4 (N1’-Ph C-4), 129.2 (N1’-Ph C-3,5), 128.4 (CH2-Ph C-
2,6), 128.3 (CH2-Ph C-1), 125.5 (N1’-Ph C-2,6), 114.1 (CH2-Ph C-3,5), 108.2
(C-4’, 3J(C-4’,3’-Me) = 2.7 Hz), 94.9 (C-4, 1J(C-4,H-4) = 183.4 Hz, 2J(C-4,H-
2
N
O
N
4'
5'
2'
N
1
8b
N
Cl
1'
1
1
5) = 10.5 Hz), 55.2 (O-Me, J = 143.8 Hz), 51.3 (CH2, J = 140.0 Hz,
3J(CH2,Ph-H-2,6) = 4.3 Hz), 14.8 (3’-Me, 1J = 129.6 Hz); 15N-NMR (50 MHz,
CDCl3): δ (ppm) −185.1 (N-1), −165.7 (N-1’), −95.3 (N-2), −75.7 (N-2’); IR:
1745 (C=O) cm-1; MS m/z (%): 422 (M+, 0.1), 219 (100), 121 (25), 77 (20).
Calcd. for C22H19ClN4O3 (422.86): C, 62.49; H, 4.53; N, 13.25. Found: C,
62.45; H, 4.40; N, 13.15.
OMe

Molecules 2010, 15
6117
3.2.6. Cyclization of 4-Aroylpyrazolones 3a-g: General procedure for the synthesis of 4a-b, 4d-g
Under anhydrous conditions, K2CO3 (138 mg, 1 mmol) was added to a solution of the appropriate
type 3 compound (1 mmol) in dry DMF (10 mL), then the mixture was heated to reflux for 2 h. After
evaporation of the solvent, 20 mL of H2O were added to the residue. The precipitate was filtered off,
washed with water and recrystallized from EtOH. NMR data of the products are given in Tables 2-5.
1,7-Diphenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-one (4a). Starting from 3a (365 mg, 1 mmol)
304 mg (93%) of compound 4a were obtained as colorless crystals; m.p. 256 ºC (EtOH); IR: 1673
(C=O) cm-1; MS m/z (%): 328 (M+, 77), 187 (30), 77 (100), 51 (40). Calcd. for C19H12N4O2 (328.32):
C, 69.51; H, 3.68; N, 17.06. Found: C, 69.36; H, 3.53; N, 16.84.
3-Methyl-1,7-diphenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-one (4b). Starting from 3b (379 mg,
1 mmol) 288 mg (84%) of compound 4b were obtained as colorless crystals. Alternatively, starting
from 3c (379 mg, 1 mmol) 219 mg (64%) of compound 4b were obtained as colorless crystals; m.p.
220 ºC (EtOH); IR: 1664 (C=O) cm-1; MS m/z (%): 342 (M+, 66), 156 (14), 91 (24), 77 (100), 67 (20),
51 (45). Calcd. for C20H14N4O2 (342.35): C, 70.14; H, 4.12; N, 16.37. Found: C, 69.93; H, 3.96; N, 16.34.
3,5-Dimethyl-1,7-diphenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-one (4d). Starting from 3d
(393 mg, 1 mmol) 264 mg (74%) of compound 4d were obtained as colorless crystals; m.p. 243 ºC
(EtOH) (lit. [29] m.p. 240–241 ºC). IR: 1521 (C=O) cm-1; MS m/z (%): 356 (M+, 100), 178 (10), 156
(18), 91 (31), 77 (99), 67 (30), 51 (41). Calcd. for C21H16N4O2 (356.37)•0.2 H2O: C, 70.07; H, 4.59; N,
15.72. Found: C, 69.96; H, 4.38; N, 15.56.
1,3-Dimethyl-7-phenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-one (4e). Starting from 3e (317 mg,
1 mmol) 185 mg (66%) of compound 4e were obtained as colorless crystals; m.p. 204 ºC (EtOH); IR:
1654 (C=O) cm-1; MS m/z (%): 280 (M+, 100), 139 (25), 77 (74), 51 (43). Calcd. for C15H12N4O2
(280.28): C, 64.28; H, 4.32; N, 19.99. Found: C, 64.17; H, 4.23; N, 19.82.
1-(4-Methoxybenzyl)-7-phenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-one (4f). Starting from 3f
(409 mg, 1 mmol) 276 mg (74%) of compound 4f were obtained as colorless crystals; m.p. 245 ºC
(EtOH); IR: 1667 (C=O) cm-1; MS m/z (%): 372 (M+, 20), 121 (100), 77 (15). Calcd. for C21H16N4O3
(372.38): C, 67.73; H, 4.33; N, 15.05. Found: C, 67.78; H, 4.18; N, 14.97.
1-Benzyl-3-methyl-7-phenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4-(7H)-one (4g). Starting from 3g
(393 mg, 1 mmol) 258 mg (73%) of compound 4g were obtained as colorless crystals; m.p. 210 ºC
(EtOH); IR: 1659 (C=O) cm-1; MS m/z (%): 356 (M+, 39), 265 (33), 91 (100), 77 (28), 51 (14). Calcd.
for C21H16N4O2 (356.38): C, 70.77; H, 4.53; N, 15.72. Found: C, 70.89; H, 4.34; N, 15.64.

Molecules 2010, 15
6118
3.2.7. General procedure for the synthesis of 5a-b and 5d-g
Lawesson’s Reagent (202 mg, 0.5 mmol) was added to a solution of the appropriate oxo compound
4 in 15 mL of toluene and the mixture was heated to reflux for approx. 14 h. After cooling, the
precipitate was filtered off and recrystallized from EtOH. In case of 5b no precipitate was formed, here
the solvent was evaporated and the residue was subjected to column chromatography (silica gel,
mobile phase CH2Cl2:MeOH/9:1) in order to obtain the colored thione which was crystallized from
EtOH for analytical purposes. NMR data of the products are given in Tables 2-5.
1,7-Diphenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-thione (5a). Starting from 4a (328 mg, 1 mmol)
204 mg (60%) of compound 5a were obtained as reddish crystals; m.p. 254–256 ºC (EtOH); MS m/z
(%): 344 (M+, 100), 201 (30), 77 (84), 51 (57). Calcd. for C19H12N4OS (344.39)•0.2 H2O: C, 65.58; H,
3.59; N, 16.10. Found: C, 65.57; H, 3.37; N, 15.73.
3-Methyl-1,7-diphenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-thione (5b). Starting from 4b resp. 4c
(342 mg, 1 mmol) 356 mg (99%) of compound 5b were obtained as orange crystals; m.p. 195–197 ºC
(EtOH); MS m/z (%): 358 (M+, 22), 356 (100), 77 (50), 51 (25). Calcd. for C20H14N4OS (358.42): C,
67.02; H, 3.94; N, 15.63. Found: C, 67.03; H, 3.82; N, 15.57.
3,5-Dimethyl-1,7-diphenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-thione (5d). Starting from 4d
356 mg, 1 mmol) 268 mg (72%) of compound 5d were obtained as deep yellow crystals; m.p. 286 ºC
(EtOH) (lit. [29] m.p. 285–286 ºC); MS m/z (%): 373 (M++1, 23), 372 (M+, 100), 186 (11), 77 (46), 51
(27).
1,3-Dimethyl-7-phenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-thione (5e). Starting from 4e (280 mg,
1 mmol) 138 mg (47%) of compound 5e were obtained as yellowish crystals; m.p. 212 ºC (EtOH); MS
m/z (%): 296 (M+, 18), 275 (42), 73 (100). Calcd. for C15H12N4OS (296.35): C, 60.79; H, 4.08; N,
18.91. Found: C, 60.77; H, 3.94; N, 18.58.
1-(4-Methoxybenzyl)-7-phenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-thione (5f). Starting from 4f
(372 mg, 1 mmol) 314 mg (81%) of compound 5f were obtained as yellowish crystals; m.p. 222 ºC
(EtOH); MS m/z (%): 388 (M+, 13), 121 (100), 91 (10), 77 (31), 51 (14). Calcd. for C21H16N4O2S
(388.44)•0.2 H2O: C, 64.34; H, 4.22; N, 14.29. Found: C, 64.40; H, 3.96; N, 14.12.
1-Benzyl-3-methyl-7-phenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4-(7H)-thione (5g). Starting from 4g
(356 mg, 1 mmol) 268 mg (72%) of compound 5g were obtained as yellowish crystals; m.p. 224 ºC
(EtOH); MS m/z (%): 373 (M++1, 21), 372 (M+, 100), 281 (75), 91 (97), 77 (37), 51 (33). Calcd. for
C21H16N4OS (372.44): C, 67.72; H, 4.33; N, 15.04. Found: C, 67.37; H, 4.15; N, 14.85.
3.2.8. General procedure for the synthesis of 4x and 5x
Under anhydrous conditions, a solution of the PMB-substituted congener 4f or 5f (0.5 mmol) and
trifluoroacetic acid (TFA, 1.43 g, 12.5 mmol) was heated to reflux overnight. After removal of excess

Molecules 2010, 15
6119
TFA under reduced pressure the residue was stored over solid KOH. Then ice-cold diethyl ether-
acetone (3:1) was added. The precipitate was filtered off and washed with cold diethyl ether-acetone.
NMR data of the products are given in Tables 2-5
1-Phenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-one (4x). Starting from 4f (186 mg, 0.5 mmol)
61 mg (48%) of compound 4x were obtained as brown powder; m.p. 327–329 ºC; IR: 1681 (C=O) cm-
1; MS m/z (%): 253 (M++1, 16), 252 (M+, 100), 111 (87), 77 (46), 51 (38). HRMS Calcd. for
C13H8N4O2: 252.0647. Found: 252.0644.
1-Phenyl-1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-thione (5x). Starting from 5f (194 mg, 0.5 mmol)
69 mg (51%) of compound 5x were obtained as a greenish powder; m.p. 271–273 ºC; MS m/z (%): 269
(M++1, 18), 268 (M+, 100), 267 (M+-1, 45)127 (43), 77 (54), 51 (45). HRMS Calcd. for C13H7N4OS
(M+-1): 267.0341. Found: 267.0335.
Table 2. 1H-NMR chemical shifts of 4a-b, 4d-g, 5a-b, 5d-g, 4x and 5x (δ in ppm).
Comp
4a
Solvent
CDCl3
H of R1
Ph: 7.82 (2,6), 7.55 (3,5),
7.44 (4)
H of R3
8.22 (H-3)
H of R5
8.22 (H-5)
H of R7
Ph: 7.82 (2,6), 7.55 (3,5), 7.44 (4)
CDCl3
CDCl3
Ph: 7.78 (2,6), 7.52 (3,5),
7.40 (4)
Ph: 7.78 (2,6), 7.51 (3,5),
7.39 (4)
2.66 (Me)
2.65 (Me)
8.17 (H-5)
2.65 (Me)
Ph: 7.80 (2,6), 7.53 (3,5), 7.43 (4)
Ph: 7.78 (2,6), 7.51 (3,5), 7.39 (4)
4b
4d
CDCl3
CDCl3
3.87 (Me)
2.55 (Me)
8.05 (H-3)
8.13 (H-5)
8.17 (H-5)
Ph: 7.79 (2,6), 7.56 (3,5), 7.43 (4)
Ph: 7.66 (2,6), 7.56 (3,5), 7.46 (4)
4e
4f
Ph: 7.28 (2,6), 6.89
(3,5); 5.37 (CH2), 3.79
(OMe)
CDCl3
CDCl3
CDCl3
CDCl3
Ph: 7.37 (4), 7.36 (3,5),
7.31 (2,6); 5.35 (CH2)
Ph: 7.84 (2,6), 7.57 (3,5),
7.46 (4)
Ph: 7.81 (2,6), 7.54 (3,5),
7.42 (4)
2.60 (Me)
8.39 (H-3)
2.78 (Me)
2.80 (Me)
8.12 (H-5)
8.39 (H-5)
8.32 (H-5)
2.80 (Me)
Ph: 7.60 (2,6), 7.52 (3,5), 7.42 (4)
Ph: 7.84 (2,6), 7.57 (3,5), 7.46 (4)
Ph: 7.82 (2,6), 7.55 (3,5), 7.44 (4)
Ph: 7.80 (2,6), 7.53 (3,5), 7.41 (4)
4g
5a
5b
5d
Ph: 7.80 (2,6), 7.53 (3,5),
7.41 (4)
CDCl3
CDCl3
3.89 (Me)
2.65 (Me)
8.20 (H-3)
8.27 (H-5)
8.32 (H-5)
Ph: 7.81 (2,6), 7.57 (3,5), 7.45 (4)
Ph: 7.66 (2,6), 7.56 (3,5), 7.47 (4)
5e
5f
Ph: 7.28 (2,6), 6.90
(3,5); 5.38 (CH2), 3.79
(OMe)
CDCl3
Ph: 7.38 (3,4,5), 7.33
(2,6); 5.37 (CH2)
2.73 (Me)
8.24 (H-3)
8.34 (H-3)
8.29 (H-5)
8.56 (H-5)
8.66 (H-5)
Ph: 7.61 (2,6), 7.53 (3,5), 7.43 (4)
13.78 (NH)
5g
4x
5x
DMSO-d6 Ph: 7.85 (2,6), 7.62 (3,5),
7.48 (4)
DMSO-d6 Ph: 7.87 (2,6), 7.64 (3,5),
7.50 (4)
14.00 (NH)

Molecules 2010, 15
6120
Table 3. 13C-NMR chemical shifts of 4a-b, 4d-g, 5a-b, 5d-g, 4x and 5x (δ in ppm, solvents as listed in Table 2).
Comp
4a
C-3
C-3a
C-4
C-4a
C-5
C-7a
C-8a
C of R1
C of R3 C of R5
C of R7
136.7
108.8
169.7
108.8
136.7
151.3
151.3
Ph: 136.6 (1), 129.6 (3,5),
128.3 (4), 121.3 (2,6)
Ph: 136.6 (1), 129.48 (3,5),
127.8 (4), 121.1 (2,6)
Ph: 136.7 (1), 129.5 (3,5),
127.7 (4), 121.0 (2,6)
34.1 (Me)
-
-
Ph: 136.6 (1), 129.6 (3,5), 128.3
(4), 121.3 (2,6)
Ph: 136.7 (1), 129.53 (3,5), 128.1
(4), 121.2 (2,6)
Ph: 136.7 (1), 129.5 (3,5), 127.7
(4), 121.0 (2,6)
Ph: 136.7 (1), 129.6 (3,5), 128.1
(4), 121.5 (2,6)
148.1
148.0
146.8
135.5
106.5
106.6
105.0
107.8
170.6
171.8
170.7
169.8
108.9
106.6
108.7
108.6
136.6
148.0
136.6
136.7
151.3
151.5
151.3
151.4
151.4
151.5
152.6
152.0
14.0
(Me)
14.0
(Me)
13.9
(Me)
-
-
4b
4d
4e
4f
14.0
(Me)
-
Ph: 159.9 (4), 129.4 (2,6),
126.2 (1), 114.4 (3,5); 55.3
(OMe), 52.4 (CH2)
Ph: 134.6 (1), 129.0 (3,5),
128.6 (4), 127.7 (2,6); 52.3
(CH2)
-
-
-
Ph: 136.6 (1), 129.6 (3,5), 128.2
(4), 121.6 (2,6)
146.9
138.1
105.5
117.8
170.7
192.1
108.8
117.8
136.6
138.1
151.3
145.5
152.4
145.5
14.0
(Me)
Ph: 136.7 (1), 129.5 (3,5), 128.0
(4), 121.4 (2,6)
4g
5a
Ph: 136.6 (1), 129.7 (3,5),
128.3 (4), 121.3 (2,6)
-
Ph: 136.6 (1), 129.7 (3,5), 128.3
(4), 121.3 (2,6)
150.1
150.2
148.8
136.9
114.8
115.1
113.5
117.0
193.5
195.5
193.5
192.2
118.1
115.1
117.7
117.5
138.2
150.2
138.1
138.1
145.1
145.8
145.3
145.5
146.0
145.8
147.3
146.2
Ph: 136.4 (1), 129.56 (3,5),
128.0 (4), 121.2 (2,6)
Ph: 136.5 (1), 129.6 (3,5),
127.9 (4), 121.2 (2,6)
34.2 (Me)
15.6
(Me)
15.9
(Me)
15.2
(Me)
-
-
Ph: 136.6 (1), 129.6 (3,5), 128.2
(4), 121.1 (2,6)
Ph: 136.5 (1), 129.6 (3,5), 127.9
(4), 121.2 (2,6)
Ph: 136.7 (1), 129.6 (3,5), 128.2
(4), 121.4 (2,6)
Ph: 136.5 (1), 129.6 (3,5), 128.3
(4), 121.5 (2,6)
5b
5d
5e
5f
15.9
(Me)
-
Ph: 159.9 (4), 129.4 (2,6),
126.0 (1), 114.4 (3,5); 55.3
(OMe), 52.5 (CH2)
Ph: 134.4 (1), 129.1 (3,5),
128.7 (4), 127.8 (2,6); 52.4
(CH2)
-
-
148.9
114.1
193.6
117.9
138.2
145.2
147.0
15.4
(Me)
Ph: 136.6 (1), 129.6 (3,5), 128.1
(4), 121.3 (2,6)
5g
136.3
137.7
107.4
116.9
170.5
193.5
106.7
115.8
128.6
130.2
160.6
155.0
153.0
147.6
Ph: 136.5 (1), 129.6 (3,5),
128.0 (4), 121.8 (2,6)
Ph: 136.3 (1), 129.6 (3,5),
128.2 (4), 121.8 (2,6)
-
-
-
-
-
-
4x
5x

Molecules 2010, 15
6121
Table 4. Selected 13C,1H spin coupling constants of 4a-b, 4d-g, 5a-b, 5d-g, 4x and 5x (Hz,
solvents as listed in Table 2).
Comp
4a
J of C-3
1J = 194.7
J of C-3a
2J(H-3) =
J of C-4a
2J(H-5) =
J of C-5
1J = 194.7
J of C-7a
3J(H-5) =
J of C-8a
3J(H-3) =
other couplings
9.9
9.9
5.2
5.2
2J(3-Me) = 3J(3-Me) = 2J(H-5) =
7.2 2.9 10.0
2J(3-Me) = 3J(3-Me) = 3J(5-Me) = 2J(5-Me) =
1J = 194.4
3J(H-5) =
1J(3-Me) = 129.4
4b
4d
5.1
1J(3-Me) = 129.3, 1J(5-Me) =
7.1
2.7
2.7
7.1
129.3
2J(3-Me) = 3J(3-Me) = 2J(H-5) =
1J = 194.1
3J(H-5) =
3J(N-Me) 1J(N-Me) = 141.7, 1J(3-Me) =
4e
4f
7.1
2.6
9.9
5.2
= 2.1
129.1
1J = 194.1
2J(H-3) =
2J(H-5) =
1J = 194.6
3J(H-5) =
3J(H-3) ~
1J(OMe) = 144.1, 1J(N-CH2)
10.0
9.9
5.2
5.2, 3J(N- = 141.5, 3J(NCH2,Ph H-2,6) =
CH2) = 2.8
4.9, 2J(Ph C-1,NCH2) = 4.7,
3J(Ph C-2/6,NCH2) = 4.4
2J(3-Me) = 3J(3-Me) = 2J(H-5) =
1J = 194.2
1J = 195.8
1J = 195.5
3J(H-5) =
3J(N-CH2) 1J(N-CH2) = 141.0, 1J(3-Me)
4g
5a
7.1
2.8
10.0
5.2
= 2.7
= 129.2, 3J(NCH2,Ph H-2,6) =
4.7
1J = 195.8
2J(H-3) =
2J(H-5) =
3J(H-5) =
3J(H-3) =
9.3
9.3
5.1
5.1
2J(3-Me) = 3J(3-Me) = 2J(H-5) =
7.1 2.6 9.1
2J(3-Me) = 3J(3-Me) = 3J(5-Me) = 2J(5-Me) =
3J(H-5) =
1J(3-Me) = 129.7
5b
5d
5.0
1J(3-Me) = 129.6, 1J(5-Me) =
7.2
2.5
2.5
7.2
129.6
2J(3-Me) = 3J(3-Me) = 2J(H-5) =
1J = 195.3
3J(H-5) =
3J(N-Me) 1J(N-Me) = 141.9, 1J(3-Me) =
5e
5f
7.1
2.7
9.1
5.1
= 2.4
129.4
1J = 195.0
2J(H-3) =
2J(H-5) =
1J = 195.5
1J = 195.3
1J ~ 195.0
1J = 195.9
3J(H-5) =
3J(H-3) =
1J(OMe) = 144.1, 1J(N-CH2)
9.4
9.3
5.1
5.1, 3J(N- = 141.4, 3J(NCH2,Ph H-2,6) =
CH2) = 2.6
4.6
2J(3-Me) = 3J(3-Me) = 2J(H-5) =
3J(H-5) =
3J(N-CH2) 1J(N-CH2) = 141.2, 1J(3-Me)
5g
4x
5x
7.1
2.7
9.2
5.1
= 2.8
= 129.5, 3J(NCH2, Ph H-2,6)
= 4.4
1J = 193.8
2J(H-3) =
2J(H-5) ~
3J(H-5) =
not
resolved
3J(H-3) =
10.2
8.5
5.2
1J = 194.7
2J(H-3) =
2J(H-5) =
3J(H-5) =
3J(H-3) =
9.5
7.8
8.5
4.9

Molecules 2010, 15
Table 5. 15N-NMR chemical shifts of investigated compounds (δ in ppm, solvents as listed in Table 2).
6122
Comp
4a
4b
4d
4e
N-1
N-2
N-6
−86.8
−87.7
−94.2
−88.0
−87.5
−88.2
−84.5
−85.5
−92.9
−85.6
−84.9
−85.8
−179.2*
−175.5*
N-7
−186.8
−193.1
−193.4
−211.8
−191.8
−200.0
−187.6
−195.3
−196.2
−213.7
−192.4
−201.9
−186.4
−186.7
−86.8
−93.6
−94.2
−91.7
−85.2
−91.3
−84.5
−92.1
−92.9
−89.7
−82.2
−89.5
−87.7
−84.3
−186.8
−187.1
−193.4
−187.5
−187.3
−187.4
−187.6
−188.0
−196.2
−188.2
−187.9
−188.2
−179.2*
−175.5*
4f
4g
5a
5b
5d
5e
5f
5g
4x
5x
* Not unambiguously classifiable.
3.2.9. General procedure for the synthesis of 9a and 9b
According to a known procedure [24], to a solution of the corresponding carboxylic acid 7 (5
mmol) in absolute ethanol (30 mL), H2SO4 (2 mL) was added and the mixture was refluxed for 8 h.
After the reaction mixture was concentrated in vacuo, the residue was neutralized with a saturated
solution of NaHCO3 and then extracted with dichloromethane (3 × 15 mL). Organic layers were
combined and dried over sodium sulfate. The solvent was evaporated and the residue was purified by
column chromatography (silica gel, mobile phase CH2Cl2:MeOH/9:1).
Ethyl 5-chloro-1-phenyl-1H-pyrazole-4-carboxylate (9a). Starting from 7a (1.11 g, 5 mmol) 1.02 g
1
(81%) of compound 9b were obtained as colorless crystals; m.p. 57 ºC (lit. [46] m.p. 59–60 ºC); H-
NMR (500 MHz, CDCl3): δ (ppm) 8.12 (s, 1H, H-3), 7.44–7.56 (m, 5H, Ph-H), 4.36 (q, 7.1 Hz, 2H,
OCH2), 1.38 (t, 7.1 Hz, 3H, Me); 13C-NMR (125 MHz, CDCl3): δ (ppm) 161.5 (C=O,
3J(CO,OCH2) = 3.3 Hz), 142.3 (C-3, 1J(C-3,H-3) = 193.6 Hz), 137.4 (Ph C-1), 131.1 (C-5, 3J(C-5,H-3)
= 5.4 Hz), 129.2 (Ph C-4), 129.1 (Ph C-3,5), 125.5 (Ph C-2,6), 112.3 (C-4, 2J(C-4,H-3) = 8.7 Hz), 60.6
(OCH2, 1J
=
147.7 Hz; 2J(OCH2,Me)
=
4.4 Hz), 14.3 (Me, 1J
=
127.1 Hz;
15
2J(Me,OCH2) = 2.7 Hz); N-NMR (50 MHz, CDCl3): δ (ppm) −162.0 (N-1), −75.8 (N-2); MS m/z
(%): 250/252 (M+, 34/11), 222 (37), 205 (100), 77 (89), 51 (61).
Ethyl 5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxylate (9b). Starting from 7b (1.18 g, 5 mmol)
688 mg (52%) of compound 9b were obtained as colorless crystals; m.p. 72–73 ºC (lit. [47]
1
m.p. 74 ºC); H-NMR (500 MHz, CDCl3): δ (ppm) 7.41 (m, 2H, Ph H-2,6), 7.36 (m, 2H, Ph H-3,5),
13
7.30 (m, 1H, Ph H-4), 4.24 (q, 7.1 Hz, 2H, OCH2), 2.43 (s, 3H, 3-Me), 1.27 (t, 7.1 Hz, 3H, Me); C-
NMR (125 MHz, CDCl3): δ (ppm) 161.9 (CO, 3J(CO,CH2) = 3.1 Hz), 151.7 (C-3,
2J(C-3,3-Me) = 7.0 Hz), 137.2 (Ph-C-1), 130.8 (C-5), 128.7 (Ph C-3,5), 128.5 (Ph C-4), 125.1 (Ph C-
3
1
2,6), 109.8 (C-4, J(C-4,3-Me) = 2.7 Hz), 59.9 (OCH2, J = 147.6 Hz, 2J(OCH2,CH2) = 4.4 Hz), 14.4
1
1
2
15
(3-Me, J = 129.2 Hz), 13.9 (ester-Me, J = 127.0 Hz, J(CH3,CH2) = 2.6 Hz); N-NMR (50 MHz,

Molecules 2010, 15
6123
CDCl3): δ (ppm) −168.2 (N-1), −77.6 (N-2); MS m/z (%): 264/266 (M+, 53/18), 219 (100), 155 (12),
77 (56), 51 (26).
4. Conclusions
Starting from appropriately substituted 2-pyrazolin-5-ones we have presented a widely applicable
method for the preparation of substituted 1H-pyrano[2,3-c:6,5-c]dipyrazol-4(7H)-ones. Moreover,
conversion of the latter into the corresponding thiones has been performed. Detailed NMR
spectroscopic studies of the title compounds and their precursors were provided.
Acknowledgements
We are grateful to L. Jirovetz and Ing. P. Unteregger for recording the mass spectra.
References and Notes
1. Pinto, M.M.M.; Sousa, M.E.; Nascimento, M.S.J. Xanthone Derivatives: New insights in
biological activities. Curr. Med. Chem. 2005, 12, 2517–2538.
2. El-Seedi, H.R.; El-Barbary, M.A.; El-Ghorab, D.M.H.; Bohlin, L.; Borg-Karlson, A.-K.;
Goeransson, U.; Verpoorte, R. Recent insights into the biosynthesis and biological activities of
natural xanthones. Curr. Med. Chem. 2010, 17, 854–901.
3. Na, Y. Recent cancer drug development with xanthone structures. J. Pharm. Pharmacol. 2009,
61, 707–712.
4. Suphavanich, K.; Maitarad, P.; Hannongbua, S.; Sudta, P.; Suksamrarn, S.; Tantirungrotechai, Y.;
Limtrakul, J. CoMFA and CoMSIA studies on a new series of xanthone derivatives against the
oral human epidermoid carcinoma (KB) cancer cell line. Monatsh. Chem. 2009, 140, 273–280.
5. Woo, S.; Jung, J.; Lee, C.; Kwon, Y.; Na, Y. Synthesis of new xanthone analogues and their
biological activity test – Cytotoxicity, topoisomerase II inhibition, and DNA cross-linking study.
Bioorg. Med. Chem. Lett. 2007, 17, 1163–1166.
6. Demirkiran, O. Xanthones in Hypericum: synthesis and biological activities. Topics Heterocycl.
Chem. 2007, 9, 139–178.
7. Fotie, J.; Bohle, D.S. Pharmacological and biological activities of xanthones. Anti-infective
Agents Med. Chem. 2006, 5, 15–31.
8. Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D. Pharmaceutical Substances: Syntheses,
Patents, Applications, 4th ed.; Thieme: Stuttgart, Germany, 2001; p. 99.
9. Eller, G.A.; Wimmer, V.; Haring, A.W.; Holzer, W. An Efficient Approach to Heterocyclic
Analogues of Xanthone: A Short Synthesis of all possible Pyrido[5,6]pyrano[2,3-c]pyrazol-
4(1H)-ones. Synthesis 2006, 4219–4229.
10. Eller, G.A.; Haring, A.W.; Datterl, B.; Zwettler, M.; Holzer, W. Tri- and Tetracyclic
Heteroaromatic Systems: Synthesis of Novel Benzo-, Benzothieno- and Thieno-Fused pyrano[2,3-
c]pyrazol-4(1H)-ones. Heterocycles 2007, 71, 87–104.

Molecules 2010, 15
6124
11. Eller, G.A.; Holzer, W. A Convenient Approach to Heterocyclic Building Blocks: Synthesis of
Novel Ring Systems Containing a [5,6]pyrano[2,3-c]pyrazol-4(1H)-one Moiety. Molecules 2007,
12, 60–73.
12. Eller, G.A.; Datterl, B.; Holzer, W. Pyrazolo[4’,3’:5,6]pyrano[2,3-b]quinoxalin-4(1H)-one:
Synthesis and Characterization of a Novel Tetracyclic Ring System. J. Heterocycl. Chem. 2007,
44, 1139–1143.
13. Eller, G.A.; Wimmer, V.; Holzer, W. Synthesis of Novel Polycyclic Ring Systems Containing two
Pyrano[2,3-c]pyrazol-4(1H)-one Moieties. Khim. Geterotsikl. Soedin. 2007, 1251–1255 (Chem.
Heterocycl. Comp. 2007, 43, 1060–1064).
14. Eller, G.A.; Habicht, D.; Holzer, W. Synthesis of a Novel Pentacycle: 8-Methyl-10-
phenylpyrazolo[4’,3’:5,6]pyrano[3,2-c][1,10]phenanthrolin-7(10H)-one.
Soedin. 2008, 884–890 (Chem. Heterocycl. Comp. 2008, 44, 709–714).
Khim.
Geterotsikl.
15. Eller, G.A.; Zhang, Q.; Habicht, D.; Datterl, B.; Holzer, W. Synthesis and NMR Data of
Pyrazolo[4’,3’:5,6]pyrano[2,3-b]pyrazin-4(1H)-ones: Derivatives of a Novel Tricyclic Ring
System. Acta Chim. Slov. 2009, 56, 521–526.
16. Batezila, G.; Holzer, W. (2-Chlorophenyl)-3-methylchromeno[2,3-c]pyrazol-4(1H)-one. Molbank
2010, M 661.
17. Jensen, B.S. The Synthesis of 1-Phenyl-3-methyl-4-acyl-pyrazolones-5. Acta Chem. Scand. 1959,
13, 1668–1670; (Chem. Abstr. 1962, 56, 66890).
18. Williams, A.C.; Camp, N. Product Class 4: Benzopyranones and Benzopyranthiones. Sci. Synth.
2003, 14, 347–638.
19. Huemer, V.; Eller, G.A.; Holzer, W. Heterocyclic analogs of xanthiones: 5,6-fused 3-methyl-1-
phenylpyrano[2,3-c]pyrazol-4(1H)thiones – synthesis and NMR (1H, 13C, 15N) data. Magn. Reson.
Chem. 2010, 48, 476–482.
20. Huemer, V.; Holzer, W. 1-Phenylpyrazolo[4’,3’:5,6]pyrano[2,3-c]pyridine-4(1H)thione. Molbank
2010, M 678.
21. Eller, G.A.; Holzer, W. The 4-methoxybenzyl (PMB) function as a versatile protecting group in
the synthesis of N-unsubstituted pyrazolones. Heterocycles 2004, 63, 2537–2555.
22. Jones, G.; Stanforth, S.P. The Vilsmeier reaction of fully conjugated carbocycles and
heterocycles. Org. React. 1997, 49, 1–330.
23. Zhang, X.-Li; Lu, X.-H.; Jiang, W.-Q. Synthesis of 5-chloro-N-[[(fluorophenyl)amino]-
thioxomethyl]-3-methyl-1-phenyl-1H-pyrazole-4-carboxamide derivatives and determination of
their activity as agrochemical fungicides. Yingyong Huaxue 2008, 25, 459–463.
24. Baraldi, P.G.; Tabtizi, M.A.; Preti, D.; Bovero, A.; Fruttarolo, F.; Romagnoli, R.; Zaid, N.A.;
Moorman, A.R.; Varani, K.; Borea, P.A. New 2-Arylpyrazolo[4,3-c]quinoline Derivatives as
Potent and Selective Human A3 Adenosine Receptor Antagonists. J. Med. Chem. 2005, 48,
5001–5008.
25. Haider, N.; Heinisch, G. Pyridazines. III. A Novel Approach to Pyrido[2,3-d]pyridazines by
Annelation of the Pyridine Ring to the 1,2-Diazine System. Synthesis 1986, 862–864.
26. Cherkasov, R.A.; Kutyrev, G.A.; Pudovik, A.N. Organothiophosphorus reagents in organic
synthesis. Tetrahedron 1985, 41, 2567–2624.

Molecules 2010, 15
6125
27. Pedersen, B.S.; Scheibye, S.; Nilsson, N.H.; Lawesson, S.-O. Studies on organophosphorus
compounds. XX. Syntheses of thioketones. Bull. Soc. Chim. Belg. 1978, 87, 223–228.
28. Jesberger, M.; Davis, T.P.; Barner, L. Applications of Lawesson’s reagent in organic and
organometallic syntheses. Synthesis 2003, 13, 1929–1958.
29. Sarenko, A.S.; Kvitko, I.Ya.; Efros, L.S. Heterocyclic analoges of xanthones. II. C-Acylation of
5-pyrazolinones and synthesis of chromono[3,2-d]pyrazoles. Khim. Geterotsikl. Soedin. 1972, 6,
799–804; (Chem. Heterocycl. Comp. 1972, 8, 722–727).
30. Braun, S.; Kalinowski, H.-O.; Berger, S. 150 and More Basic NMR Experiments, 2nd ed.; Wiley–
VCH: New York, NY, USA, 1998.
31. Bax, A. Structure determination and spectral assignment by pulsed polarization transfer via long-
range proton-carbon-13 couplings. J. Magn. Reson. 1984, 57, 314–318.
32. Jippo, T.; Kamo, O.; Nagayama, N. Determination of long-range proton-carbon 13 coupling
constants with selective two-dimensional INEPT. J. Magn. Reson. 1986, 66, 344–348.
33. Kalchhauser, H.; Robien, W. CSEARCH: A Computer Program for Identification of Organic
Compounds and Fully Automated Assignment of Carbon-13 Nuclear Magnetic Resonance
Spectra. J. Chem. Inf. Comput. Sci. 1985, 25, 103–108.
34. NMR Predict, version 4.7. Modgraph Consultants, Ltd.: Herts, UK, 2010;
www.modgraph.co.uk/product_nmr.htm (accessed on 14 June 2010).
35. ACD/C+H Predictors and DB, version 12.0. Advanced Chemistry Development, Inc.: Toronto,
ON, Canada, 2008; www.acdlabs.com (accessed on 14 June 2010).
36. Huemer, V.; Eller, G.A.; Holzer, W. Heterocyclic analogs of xanthiones: 5,6-fused 3-methyl-1-
phenylpyrano[2,3-c]pyrazol-4(1H)thiones – synthesis and NMR (1H, 13C, 15N) data. Magn. Reson.
Chem. 2010, 48, 476–482.
37. Holzer, W.; Kautsch, C.; Laggner, C.; Claramunt, R.M.; Perez-Torralba, M.; Alkorta, I.; Elguero,
J. On the tautomerism of pyrazolones: the geminal 2J[pyrazole C-4,H-3(5)] spin coupling constant
as a diagnostic tool. Tetrahedron 2004, 60, 6791–6805.
38. Begtrup, M.; Boyer, G.; Cabildo, P.; Cativiela, C.; Claramunt, R.M.; Elguero, J.; Ignacio Garcia,
J.; Toiron, C.; Vesdo, P. Carbon-13 NMR of pyrazoles. Magn. Reson. Chem. 1993, 31, 107–168.
39. Sucrow, W.; Slopianka, M. Enehydrazines, 19. Pyrazolium Betaines from 1,1-Dialkylhydrazines
and Acetylenecarboxylic Esters. Chem. Ber. 1978, 111, 780–790.
40. ACD Name, version 12.0. Advanced Chemistry Development, Inc.: Toronto, ON, Canada, 2010;
www.acdlabs.com/, (accessed on 14 June 2010).
41. Eller, G.A. Improving the quality of published chemical names with nomenclature software.
Molecules 2006, 11, 915–928.
42. Koshelev, Yu.N.; Kvitko, I.Ya.; Efros, L.S. Transfer of substituent effects in thieno[3,2-
d]pyrazole. Zh. Org. Khim. 1972, 8, 1750–1754 (J. Org. Chem. 1972, 8, 1789–1793).
43. Brack, A. Condensed pyrazolopyridines. Liebigs Ann. Chem. 1965, 681, 105–110.
44. Dickopp, H. Sydnones. II. 5-Halopyrazolecarboxylic acids. Chem. Ber. 1974, 107, 3036–3042.
45. Duquenois, P.; Amal, H. The action of PCl5 and SOCl2 on antipyrine-4-carboxylic acid. Bull. Soc.
Chim. Fr. 1942, 9, 721–725.
46. Beck, J.R.; Gajewski, R.P.; Lynch, M.P.; Wright, F.L. Nonaqueous Diazotiation of 5-Amino-1-
aryl-1H-pyrazole-4- carboxylate Esters. J. Het. Chem. 1987, 24, 267–270.

Molecules 2010, 15
6126
47. Rojahn, C.A.; Fahr, K. Synthesis of pyrazole aldehydes. I. Liebigs Ann. Chem. 1923, 434,
252–264.
Sample Availability: Samples of the compounds are available from the authors.
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).